Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Oct 4th, 2022

Antiplatelet Therapy in Patients With Coronary Artery Disease and Acute Ischemic Stroke/Transient Ischemic Attack

Experts will discuss reducing ischemic and bleeding risk with antiplatelet therapy in patients with CAD, and explain the evidence for DAPT in acute ischemic stroke/TIA and the need for its early use in appropriate individuals


Screenshot 2021 11 02 130142

This educational initiative will focus on current insights into use of antiplatelet therapy in individuals with high-risk coronary artery disease (CAD) or who have experienced an acute ischemic stroke/transient ischemic attack (TIA). Strategies with antiplatelet therapy to mitigate bleeding risk after percutaneous coronary intervention (PCI) without increasing the risk of ischemic outcomes will be identified. Settings will also be described where extended duration of dual antiplatelet therapy (DAPT) may provide net clinical benefit. In addition to clinical trial results and updated FDA labeling, current meta-analyses will be interpreted, enabling attendees to have a clearer understanding of the duration of DAPT—benefits and risks associated with short-term DAPT followed by P2Y12 inhibitor therapy, as well as with extended DAPT. Decision-making regarding the use of DAPT is also a critical component of management of patients experiencing an acute ischemic stroke or TIA. Clinicians need to recognize patients eligible for the addition of either clopidogrel or ticagrelor to aspirin (ASA) based on clinical trial evidence, and that timely initiation of DAPT is critical for reduction in risk of recurrent stroke. A common guiding principle for use of antiplatelet therapy in patients with CAD or acute ischemic stroke/TIA is a personalized approach. Therefore, in this program, experts in the use of antiplatelet therapy in CAD and acute ischemic stroke/TIA will describe best uses of antiplatelet therapy to optimize clinical outcomes in these settings.

Saturday, November 13, 2021
7:30 pm to 9:00 pm Eastern Standard Time and OnDemand

Presenters:
Deepak L. Bhatt, MD, MPH (Chair)

Professor of Medicine
Harvard Medical School, Boston, Massachusetts

Karen L. Furie, MD, MPH
Professor of Clinical Neuroscience
Chair of Neurology
The Warren Alpert Medical School of Brown University, Providence, Rhode Island

S. Claiborne Johnston, MD, PhD
Special Assistant to the President and Provost
Professor of Neurology
Dell Medical School, The University of Texas at Austin, Austin, Texas

Philippe Gabriel Steg, MD
Professor of Cardiology
Université Paris–Diderot
Département de Cardiologie
Hôpital Bichat, Paris, France

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.

The American Heart Association (AHA) does not endorse any commercial products or programs. The links provided within this site are for convenience only, and are not an endorsement of either the linked-to entity, product or service.  AHA makes no warranties of any kind, express or implied, with regard to its third-party vendor websites.

Download
Interesting Stories
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
More Content
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021